The promise and challenge of new biological treatments for psoriasis: How do they impact quality of life?

Dermatologic Therapy

Volumn 17, Issue 5, 2004, Pages 376-382

  Rapp, Stephen R ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Measurement; Psoriasis; Quality of life

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

EMOTIONAL STRESS; HUMAN; PHYSICAL DISEASE; PSORIASIS; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 6344237631     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04040.x     Document Type: Review

References (41)

1. Shumaker SA, Naughton MJ. The International Assessment of Health-Related Quality of Life. In: Shumaker SA, Berzon R, eds. The international assessment of health-related quality of life: theory, translation, measurement, and analysis. New York: Rapid Communications, 1995: 3-10.
2. Sampogna F, Picardi A, Melchi CF, Pasquini P, Abeni D. The impact of skin diseases on patients: comparing dermatologists' opinions with research data collected on their patients. Br J Dermatol 2003: 148: 989-995.
3. Rapp SR, Feldman SR, Fleischer AB, et al. Care Management of Skin Disease: Life Quality and Economic Impact. In: Rajagopalan R, Sherritz E, Anderson R, eds. Health-related quality of life in psoriasis: A biopsychosocial model and measures. New York: Marcel Dekker, Inc., 1998: 125-145.
4. Fleischer AB, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. The J Invest Dermatol 1994: 102: 967-969.
5. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark AR. The physical, psychological and social impact of psoriasis. J Health Psychol 1997: 2: 525-537.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999: 41: 401-407.
7. Leary MR, Rapp SR, Herbst KC, Exum ML, Feldman SR. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol 1998: 17: 530-536.
8. Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001: 145: 610-616.
9. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medicalcare 1992: 30: 473-483.
10. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981: 19: 787-805.
11. Nanda U, McLendon PM, Andresen EM, Armbrecht E. The SIP68: an abbreviated sickness impact profile for disability outcomes research. Qual Life Res 2003: 12: 583-595.
12. de Bruin AF, Buys M, de Witte LP, Diederiks JP. The sickness impact profile: SIP68, a short generic version. First evaluation of the reliability and reproducibility. J Clin Epidemiol 1994: 47: 863-871.
13. Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med[a] 1981: 15: 221-229.
14. Skevington SM, Bradshaw J, Saxena S. Selecting national items for the WHOQOL: conceptual and psychometric considerations. Soc Sci Med 1999: 48: 473-487.
15. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 1998: 46: 1569-1585.
16. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002: 138: 1221-1227.
17. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996: 10: 644-653.
18. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000: 43: 803-808.
19. Pollard WE, Bobbitt RA, Bergner M, Martin DP, Gilson BS. The Sickness Impact Profile: reliability of a health status measure. Med Care 1976: 14: 146-155.
20. Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health 1975: 65: 1304-1310.
21. Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976: 6: 393-415.
22. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med Care 1976: 14: 57-67.
23. Carter WB, Bobbitt RA, Bergner M, Gilson BS. Validation of an interval scaling: the sickness impact profile. Health Serv Res 1976: 11: 516-528.
24. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and psoriasis Disability index in psoriasis. Br J Dermatol 1990: 123: 751-756.
25. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994: 19: 210-216.
26. Fredricksson T, Petterson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978: 157: 238-244.
27. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001: 144: 967-972.
28. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003: 1: 53.
29. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996: 107: 707-713.
30. Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2242 dermatological outpatients. Dermatology 2002: 204: 43-49.
31. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med 2001: 5: 105-110.
32. Finlay AY, Kelly S. Psoriasis - An index of disability. Clin Exp Dermatol 1987: 12: 8-11.
33. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003: 4: 131-139.
34. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004: 150: 317-326.
35. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003: 206: 307-315.
36. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003: 290: 3073-3080.
37. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004: 3: 27-38.
38. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003: 349: 2014-2022.
39. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003: 48: 829-835.
40. Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 2003: 44: 116-120.
41. Hitt E. Infliximab improves quality of life in patients with severe psoriasis. [WWW document.] http://www.medscape.com/ viewarticle/469066. (Accessed March 27, 2004.)